

4-17-00

A

EXPRESS MAIL CERTIFICATE

Date 4/14/00 Label No EL503340903

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by Express Mail Post Office to Addressee" service.

D Beck D Beck
Name (Print) Signature

04/14/00
jc604 U.S. PTO

JC600 U.S. PTO
09/549858
04/14/00

File No: 0882/1D235-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

James McSHANE, Ray WOOD, Sumio WATANABE, Kiyoshi IWAMOTO and Katsumi ONAI

Serial No: To be Assigned
Filed: Concurrently Herewith
For: PHARMACEUTICAL FORMULATION COMPRISING GLYCINE AS A STABILIZER

PCT CONTINUING APPLICATION

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

This is a continuation application under 35 U.S.C. § 111 of the above-identified international application designating the United States. The following are enclosed.


- 1. A copy of the international application as originally filed.
- 2. [X] Declaration and Power of Attorney (unsigned)

09549858-04-14-00

3. ☒ Formal drawings, 5 sheets (Figs. 1 to 9)
☐ Informal drawings, sheets (Figs. to)
4. ☐ Assignment for recording to: __
5. ☐ Check in amount of \$, (filing; recording)
(See attached Fee Computation Sheet)
6. ☐ Verified statement claiming small entity status.
7. ☐ Cancel claims .
8. ☒ Amend the specification by inserting before the first line the sentence:
"This is a continuation of International Application No.
PCT/US98/21972, filed September 14, 1998, which claims priority
under 35 U.S.C. § 119(e) of provisional application serial no.
60/062,089 filed October 14, 1997. The entire disclosure of both of
these applications is hereby incorporated by reference."
9. ☒ A Preliminary Amendment is also enclosed.
10. ☐ Priority is claimed for this application, corresponding application/s
having been filed as follows:

Country:
Number:
Date:

Respectfully submitted,



John C. Todaro
Reg. No. 36,036
Attorney for Applicant

Date: April 14, 2000

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022
212-527-7700

::ODMA\WORLD\OX\IM\0882\1D235\LWJ3968 WPD

EXPRESS MAIL CERTIFICATE

Date 4/14/00 Label No. 2503340903

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

D B Peck [Signature]
Name (Print) Signature

File No: 0882/1D235-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

James McSHANE, Ray WOOD, Sumio WATANABE, Kiyoshi IWAMOTO and Katsumi ONAI

Serial No: To be Assigned

Filed: Concurrently Herewith

For: PHARMACEUTICAL FORMULATION COMPRISING GLYCINE AS A STABILIZER

PRELIMINARY AMENDMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

Prior to examination of this application, please amend the title as follows:

PHARMACEUTICAL FORMULATION COMPRISING GLYCINE AS A STABILIZER [AND METHOD OF PREPARATION]

004400-04400

REMARKS

Favorable action is earnestly solicited.

Respectfully submitted,



John C. Todaro
Reg. No. 36,036
Attorney for Applicant

Date: April 14, 2000

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022
212-527-7700

00440-0504350

EXPRESS MAIL CERTIFICATE

Date 4/14/00 Label No. 52503340903

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service & that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington D.C. 20231 by "Express Mail Post Office to Addressee" service.

Name (Print) D BeckSignature D Beck


DOCKET 0882/2D235

PHARMACEUTICAL FORMULATION AND METHOD OF PREPARATION**FIELD OF THE INVENTION**

The present invention relates to the preparation of pharmaceutical formulations with anti-ulcerative properties, and in particular, formulations that are reconstituted for intravenous administration.

BACKGROUND OF THE INVENTION

Souda et al., U.S. Patent No. 5,045,552, incorporated by reference herein, describes compounds that inhibit an H^+/K^+ -ATPase present in the stomach. These compounds are useful for treatment of peptic ulcers and other disorders associated with secretion of gastric acid, such as heartburn and gastroesophageal reflux. For example, one such compound has the following structure:



and includes pharmaceutically acceptable salts of the compound. This compound is referred to herein as Compound 1.

It is desirable when preparing reconstituted solutions of such anti-ulcerative compounds that are suitable for intravenous administration, that the solubilized compounds exhibit physical and chemical stability for at least between about 6 and about 12 hours at room temperature. It has been found by the present inventors that anti-ulcerative compounds such as Compound 1 and the compounds described by general formula I below discolor when they are reconstituted, i.e., dissolved, in aqueous solutions, particularly in solutions suitable for intravenous administration, e.g., 5% dextrose or 0.9% saline. Such solutions quickly turn yellow to yellow-brown.

The compounds of the present invention have been determined to be more potent H^+/K^+ -ATPase inhibitors than omeprazole sodium. However, in order to provide clinically useful pharmaceutical formulations of the compounds disclosed herein for intravenous administration, it is first necessary to provide formulations for lyophilization and intravenous administration that do not degrade physically, chemically and/or demonstrate a change in color.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph showing the changes in absorption spectrum of compound 1 at a concentration of 4 mg/ml in 0.9 % saline at pH 10 as a function of time after dissolution, with storage at room temperature (25 °C) in the dark.

Figure 2 is a graph showing the changes in absorption spectrum of compound 1 at a concentration of 4 mg/ml in 0.9 % saline/50 mM glycine-NaOH buffer at pH 10 as a function of time after dissolution, with storage at room temperature (25 °C) in the dark.

Figure 3 is a graph showing the change in the absorption spectrum of compound 1, at a concentration of 4 mg/ml, in a solution which contain 5, 10, 25, and 50 mM glycine-NaOH buffer, indicating color change.

Figure 4 is a graph showing the change in the absorbance at 400, 450, 500, 550, 600, and 600 nm of compound 1, at a concentration of 2 mg/ml in 0.9% saline, at room temperature (25 °C) in the light, as a function of time.

Figure 5 is a graph showing the change in the absorbance at 400, 450, 500, 550, 600, and 600 nm of compound 1, at a concentration of 2 mg/ml in 0.9% saline, at room temperature (25 °C) in the dark, as a function of time.

Figure 6 is a graph showing the change in the absorbance at 400, 450, 500, 550, 600, and 600 nm of compound 1, at a concentration of 2 mg/ml in 0.9% saline, at 10 °C in the dark, as a function of time.

Figure 7 is a graph showing the change in the absorbance at 400, 450, 500, 550, 600, and 600 nm of compound 1, at a concentration of 2 mg/ml in 0.9% saline and 10 mM glycine-NaOH buffer, at room temperature (25 °C) in the light, as a function of time.

Figure 8 is a graph showing the change in the absorbance at 400, 450, 500, 550, 600, and 600 nm of compound 1, at a concentration of 2 mg/ml in 0.9% saline and 10 mM glycine-NaOH buffer, at room temperature (25 °C) in the dark, as a function of time.


Figure 9 is a graph showing the change in the absorbance at 400, 450, 500, 550, 600, and 600 nm of compound 1, at a concentration of 2 mg/ml in 0.9% saline and 10 mM glycine-NaOH buffer, at 10 °C in the dark, as a function of time.

5 DETAILED DESCRIPTION OF THE INVENTION

All patents, patent applications, and publications cited in this application are incorporated by reference in their entirety. In the case of a conflict of disclosure, the present specification is controlling.

It has now been surprisingly and unexpectedly discovered that if lyophilized compounds of general formula I below are reconstituted in isotonic solutions suitable for intravenous administration, such as 5% dextrose or 0.9% sodium chloride, that have been brought to a pH of between about 9 and about 12, preferably between about pH 10 and 11, by a glycine-sodium hydroxide buffer, such formulations are chemically and physically stable, and do not significantly change color, for at least between about 6 and about 12 hours at room temperature. It was also discovered that the compounds dissolved in such isotonic solutions are stable to color change for from between about 24 and 48 hours if kept at 5 °C. It has also been discovered that the use of glycine buffers with a pH of between about 9 and about 12, preferably between about pH 10 and 11, is beneficial in preparing lyophilized samples of the compounds of the invention.

Thus, the present invention provides pharmaceutical formulations suitable for intravenous injection comprising an anti-ulcerative agent having the following general formula:




where R^1 and R^2 are, independently, hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl or carboxyl group or a halogen atom;

X is O, S or $\begin{array}{c} \text{---N---} \\ | \\ R^3 \end{array}$ (in which R^3 stands for a hydrogen atom or a lower

alkyl, phenyl, benzyl or lower alkoxycarbonyl group); and


Z is selected from:

(1) a group of the formula:




where p is an integer of 1 to 3 and R^4 is a hydrogen atom or a lower alkyl, aryl or aralkyl group;

(2) a group of the general formula:




where q is an integer of 1 to 3 and R^5 is a halogen atom or an alkoxy carbonyl, aryl or heteroaryl group;

(3) a group of the general formula:




where r and s each independently are an integer of 1 to 5 and R^6 is a hydrogen atom or a lower alkyl group;


(4) a group of the formula:




(5) a group of the formula:



(6) a group of the formula:




(7) a group of the general formula:




where t is an integer of 0 to 2 and A is a lower alkyl, alkoxycarbonylmethyl, pyridyl or furyl


group, or a group of the general formula:



where P is selected from the group consisting of: -NH-, -O- or -S-; or a group of the general formula:



wherein R^7 is hydrogen or lower alkyl and w is from 0 to 3;

(8) a group of the general formula:  where R^8 is an

acetoxy or lower alkyl group; and

(9) a group of the general formula: $-\text{OR}^9$

where R^9 is a hydrogen atom or a lower alkyl or aryl group;

n is an integer of 0 to 2; m is an integer of 2 to 10, and

J and K are independently hydrogen or lower alkyl, with the proviso that when

Z is a group falling under the above category (9), R⁹ is a lower alkyl group and m stands for an integer of 3 to 10, and pharmaceutically acceptable salts thereof.

The pharmaceutical formulations also contain a glycine-sodium hydroxide buffer system, and an agent that imparts tonicity to the formulation (a "tonicity agent"). Such agents are well-known in the art, and include sodium chloride, dextrose, mannitol, glycerin, sucrose and lactose. Isotonic solutions possess the same osmotic pressure as blood plasma, and so can be intravenously infused into a subject without changing the osmotic pressure of the subject's blood plasma.

The definitions for R¹, R², X, n, J, K, Z and m are used consistently throughout the specification that follows and in the appended claims.

In the definition of the compounds of general formula (I), the lower alkyl group defined above with respect to R¹, R², R³, R⁴, R⁶, A, R⁷, R⁸, J, and K in compound (I) of the present invention may be straight-chain or branched alkyl groups having 1 to 6 carbon atoms. Examples include methyl, ethyl, n-propyl, n-butyl, isopropyl, isobutyl, 1-methylpropyl, tert-butyl, n-pentyl, 1-ethylpropyl, isoamyl, n-hexyl groups, and the like, among which methyl and ethyl groups are most preferred.

The lower alkoxy group and the lower alkoxy moiety of the lower alkoxycarbonyl group defined above with respect to R¹ and R² may be an alkoxy group derived from the above-defined and exemplified lower alkyl group. Methoxy and ethoxy groups are most preferred alkoxy groups.

The halogen atom defined above includes chlorine, bromine, iodine or fluorine. The aryl group defined above with respect to R⁴ and R⁵ may be, e.g., phenyl, tolyl, xylyl, naphthyl or the like which may be substituted with a lower alkoxy or hydroxyl group,


a halogen atom or the like.

Examples of the arylalkyl defined above with respect to R^4 include benzyl and phenethyl groups.

Examples of the heteroaryl group defined above with respect to R^5 include pyridyl, furyl, and thienyl groups.

In the definition of Z in general formula (I), groups (1), (2), (3), (4), (5) and (9) are preferred; group (9) is the most preferred. R^1 and R^2 are preferably both hydrogen; another preferred configuration of R^1 and R^2 is when R^1 is lower alkyl, e.g., methyl, and R^2 is hydrogen. X is preferably $-NR^3$ where R^3 is hydrogen. A preferred value for n is 1. The preferred substituents for J and K are both hydrogen or, where J is lower alkyl, e.g. methyl, K is preferably hydrogen, and when J is hydrogen K is preferably lower alkyl, e.g. methyl. Thus, J or K are independently preferably hydrogen or methyl, most preferably J is methyl and K is hydrogen.

A first preferred class of compounds included in the pharmaceutical formulations of the present invention fall within the compounds of general formula (I) are represented by the following formula (A):




where R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen; R^9 is selected from the group consisting of hydrogen, lower alkyl, and aryl; J is selected from the group consisting of hydrogen or lower alkyl; m is an integer from 2 to 10; and pharmaceutically acceptable salts thereof. In formula A, it is preferred that R^1 and R^2 are both hydrogen; also preferred is when R^1 is 5-lower alkoxy, 5-lower alkyl or 5-halogenated lower alkyl and R^2 is hydrogen. Preferred substituents at J are hydrogen or methyl; preferred values of m are from 3 to 10, the most preferred being 3; and the preferred R^9 substituents are lower alkyl or aryl. Most preferred at R^9 is methyl.

In one group of preferred compounds of formula A, R^1 and R^2 are both hydrogen, J is methyl, m is 3 and R^9 is methyl.

In a second group of preferred compounds falling within formula A, R^1 and R^2 are both hydrogen, J is hydrogen, m is 3 and R^9 is methyl.

In a third group of preferred compounds falling within formula A, R^1 and R^2 are both hydrogen, J is methyl, m is 2 and R^9 is benzyl.

A second class of compounds falling within general formula (I) for inclusion in the pharmaceutical formulations of the present invention are represented by formula (B), as follows:



where R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen; R^4 is selected from the group consisting of hydrogen, lower alkyl, aryl, and aralkyl; J is selected from the group consisting of hydrogen or lower alkyl; m is an integer from 2 to 10; p is an integer from 1 to 3; and pharmaceutically acceptable salts thereof.

10 In compounds of formula (B), the preferred substituents for R^1 and R^2 are both hydrogen; also preferred are compounds where R^1 is 5-lower alkoxy, 5-lower alkyl or 5-halogenated lower alkyl and R^2 is hydrogen. Preferred values of m are 2 or 3; preferred values of p are 2 or 3; and the preferred substituents at R^4 are methyl or benzyl. Most preferred are compounds of formula (B) where R^1 is 5-methyl, R^2 is hydrogen, J is methyl, m is 2, p is 2 and R^4 is methyl.

15

Examples of the pharmaceutically acceptable salts include salts of inorganic

acids, such as hydrochloride, hydrobromide, sulfate and phosphate; those with organic acids, such as acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, and toluenesulfonate; and those with amino acids such as arginine, aspartic acid and glutamic acid.

Some of the compounds according to the present invention can form a salt with a metal such as Na, K, Ca or Mg. These metal salts are also included among the pharmaceutically acceptable salts of the present invention. For example, compounds

represented by the general formula (I), wherein X is a group of $\begin{array}{c} \text{---N---} \\ | \\ \text{R}^3 \end{array}$ and R³ is a

hydrogen atom, or compounds represented by the general formula (I), where Z is a group of category (7) and B is an NH group, can be present as a metal salt.

The compounds of the present invention also can take the form of hydrates, prodrugs, or stereoisomers. It will be appreciated by those of ordinary skill in the art that variations and obvious modifications can be made to the presently claimed invention, said variations and modifications being within the scope of the claimed invention.

Methods for the preparation of the compounds of the stabilized formulations of the invention are disclosed in Souda et al., U.S. Patent 5,045,552.

The present invention also provides methods for the stabilization of compounds of general formula I above, both in the course of preparing lyophilized samples for reconstitution, and in reconstituted formulations suitable for intravenous administration. Prior to the present invention, the utility of glycine as a color stabilizer for solutions of the compounds of the invention was not known in the art, either in the context of preparing solutions for lyophilization, or for preparing solutions for intravenous administration.

To prepare lyophilized samples for reconstitution, a desired quantity of a compound of the invention is dissolved in a sufficient amount of an aqueous solution (i.e., an amount of solution in which the compound will completely dissolve) which also comprises a glycine-sodium hydroxide buffer such that the pH of the solution is between about 9 and 12, preferably between about pH 10 and about 11. The concentration of glycine in the solution is between about 1 and 300 mM, preferably between about 10 and about 150 mM. The concentration of compound in such solutions is generally from between about 1 mg/ml and 50 mg/ml. The solution is then lyophilized in a sealable container, such as a vial, and the container is sealed such that exchange of air between the inside of the sealable container and the external environment of the container is not possible. The container will typically contain between about 1 and 100 mg of compound, preferably between about 20 and 60 mg of compound, and most preferably about 40 mg of compound.

According to the present invention, reconstituted solutions for intravenous administration can be prepared by initially dissolving an amount of a desired lyophilized compound (plus any other solutes, such as glycine-NaOH buffer, which were lyophilized with the compound) in a sufficient amount of a sterile, aqueous solution to completely dissolve the lyophilized compound. Such initially dissolved solutions contain the original glycine-NaOH buffer system, substantially undiluted, and have a pH of from between about 10 and about 11.5. Under these conditions, as determined by the present inventors, the anti-ulcerative compounds of the invention are chemically and physically stable.

In order to deliver the compounds of the present invention intravenously, they may be dissolved in sterile solutions suitable for intravenous administration, such as normal saline (0.9% saline) or 5% dextrose. Such solutions typically have a pH of between about 4

and about 5, respectively. When the residual glycine-NaOH buffer system is diluted in the solution suitable for intravenous administration, for example a 50-fold dilution of 2 ml of a 20 mg/ml initial solution of anti-ulcerative compound, the pH of the resulting solution falls below the pH 9 to 12 range in which the anti-ulcerative compounds are most stable. Thus, according to the present invention, additional glycine-NaOH can be added to or included in the ultimate solution to be intravenously administered. The concentration of glycine-NaOH buffer in the final solution for intravenous administration should be between about 1 mM and 300 mM, preferably between about 10 mM and 150 mM, more preferably between 10 and 50 mM and most preferably between about 10 mM and 25 mM. The pH of the resulting solution should be alkaline, preferably between about pH 9 and 12, most preferably between pH 10 and 11.

The present invention is illustrated by the following examples, which are intended merely to illustrate the invention and not to limit its scope.

EXAMPLE 1: pH Studies

The chemical and physical stability of compound 1 at 8 mg/ml in a water for injection (WFI), adjusted with dilute (6 N) NaOH to pH 9.5, 10, 11, and 11.5, was evaluated at room temperature, 5 °C, and -20 °C. Chemical stability was monitored by evaluating the residual potency and impurity levels over 48 hours by HPLC. Physical stability was evaluated by measuring the rate of color formation at 405 nm and by visual observations.

The order of chemical and physical stability is pH 11.5 > pH 11 > pH 10.5 > pH 10 > pH 9.5 at 5 °C and room temperature. That is, chemical and physical stability of compound 1 is highest at pH 11.5, and decreases with pH; this effect is found at room

temperature and at reduced temperatures. Solutions at pH 9.5 began to assume a yellow color within 30 minutes; the color intensified rapidly. At room temperature, solutions at pH 10.5 were marginally stable at 24 hours with regard to chemical and physical stability; however, at cold temperatures (5°C), pH 10.5 was found to be adequate for 24 hours stability.

At pH 11 or greater and in cold temperatures, solutions of compound 1 appear to be adequately stable for the manufacture and handling in preparation for freeze drying. It was concluded that pH levels below 10.5 should be avoided.

EXAMPLE 2: Preliminary Buffer Evaluation

It is desirable that the pH of solutions of compound 1 and other compounds of the invention in 5% dextrose or normal saline remain in a range near about pH 10 to provide for an acceptable use period in a clinical setting. Phosphate and glycine buffer systems were tested. Phosphate was found to be an effective buffer in the desired pH range, but, as indicated below, precipitated during freeze-drying of samples containing it; glycine-NaOH was an effective buffer and had a stabilizing effect on color change and may affect turbidity when evaluated with compound 1.

Solutions of compound 1 in 50 mM phosphate buffer behaved similarly with regard to color formation as unbuffered compound 1 solutions (i.e., color formation was not inhibited). In 100 mM glycine/NaOH at pH values above 10, discoloration was substantially slower. Freeze-drying of compound 1 solutions in phosphate and glycine buffers yielded white, well-formed plugs. Reconstitution of the phosphate-containing plugs produced hazy solutions, i.e., precipitation. Based on this propensity to precipitate, phosphate was disqualified as a buffer

for the compounds of the invention.

EXAMPLE 3: Glycine Concentration and Temperature Studies

Compound 1 at 8 mg/ml in glycine at 0 mM, 100 mM, and 150 mM were evaluated at pH 10.5 to 11 at room temperature, 5 °C, and -20 °C. Chemical stability was monitored by measuring the residual potency and impurity levels over 48 hours. Physical stability was evaluated by measuring the rate of color formation at 405 nm and by visual observations. The results for color formation are shown in Tables 1, 2, and 3, below. A, B, and C contain 7.5 mg/ml glycine, equal to 100 mM glycine. D and E have 11.25 mg/ml glycine, equal to 150 mM glycine. F is the control without glycine. The pH of the solution is indicated in parentheses; the values in the tables are the absorbance at 405 nm.

**TABLE 1: COLOR INFORMATION
ROOM TEMPERATURE (25 °C) SAMPLES
(ABSORBANCE AT 405 nm)**

	A(11.0)	B(10.76)	C(10.5)	D(11.0)	E(10.5)	F(10.5)
0 hours	0.009	0.010	0.011	0.008	0.011	0.012
6 hours	0.034	0.048	0.066	0.032	0.056	0.188
12 hours	0.053	0.076	0.107	0.047	0.089	0.349
24 hours	0.101	0.145	0.200	0.091	0.162	0.838
48 hours	0.163	0.245	0.333	0.152	0.269	2.396

TABLE 2: REFRIGERATED SAMPLES (5 °C)

	A(11.0)	B(10.76)	C(10.5)	D(11.0)	E(10.5)	F(10.5)
0 hours	0.009	0.010	0.011	0.008	0.011	0.012
12 hours	0.015	0.016	0.020	0.012	0.017	0.052

24 hours	0.051	0.021	0.026	0.016	0.022	0.073
48 hours	0.019	0.025	0.030	0.017	0.027	0.098

TABLE 3: FROZEN SAMPLES (-20 °C)

	A(11.0)	B(10.76)	C(10.5)	D(11.0)	E(10.5)	F(10.5)
Initial	0.009	0.010	0.011	0.008	0.011	0.012
24 hours	0.011	0.012	0.0175	0.010	0.012	0.022
48 hours	0.010	0.013	0.015	0.010	0.014	0.027

No substantial difference in chemical stability was noted between 0 mM, 100 mM, and 150 mM glycine formulations. Solutions with greater glycine concentrations discolored more slowly. Solutions devoid of glycine discolored very quickly regardless of temperature conditions. At 5 °C, pH 10.5 to 11 solutions can be held for 24 hours without measurable increases in impurity levels. At room temperature, there is a <0.5% increase in impurities for the pH 11 solution, but at pH 10.5, >1 % impurities were measured at 24 hours. Color formation at 5 °C is significantly retarded compared to room temperature. Cold temperatures, i.e., those at or near 5 °C, are also preferred for the manufacture of compound 1 and the other compounds of the invention.

EXAMPLE 4: Reduced Glycine Concentration Experiments

The color change in a 4 mg/ml solution of compound 1 in 0.9% saline at pH 10, with and without 50 mM glycine-NaOH buffer, was evaluated by measurement of absorption at 405 nm as a function of time. 200 mg of compound 1 was dissolved in 50 ml of 0.9% saline, and was stored at room temperature, i.e., 25 °C, in the dark. Absorption

measurements were taken at the zero time point, and at 2, 4, 6, and 8 hours after dissolution. As can be seen from Figures 1 and 2, compound 1 discolored at a much greater rate in the glycine-free solution than in the solution that contained 50 mM glycine.


The glycine concentration-dependence of compound 1 discoloration was evaluated at 5 hours after dissolution. Compound 1 was dissolved at concentration of 4 mg/ml in 0.9% saline solution at pH 10 containing 5, 10, 25, and 50 mM glycine-NaOH buffer. As can be seen from Figure 3, at 5 hours post-dissolution, there was little difference in absorbance spectrum between the solutions, although there was a noticeably higher absorbance for the 5 mM glycine-NaOH containing solution.

EXAMPLE 5: Effect of Storage Conditions

The effect of exposure to light and temperature was evaluated as a function of time for 0.9% saline solutions containing 2 mg/ml compound 1, with or without 10 mM glycine-NaOH buffer, was evaluated by monitoring absorbance at 400, 450, 500, 600, and 650 nm. As can be seen from Figures 4 to 6, in solutions without glycine-NaOH buffer, increasing storage temperatures caused an increase in undesirable color development. The experiments also reveal that exposure to light has no detrimental effect on color development in solutions containing compound 1. These results are also found with solutions of compound 1 that do contain 10 mM glycine-NaOH buffer. However, as can be seen from Figures 7 to 9, the presence of glycine-NaOH buffer decreases absorption at all wavelengths, temperatures, and lighting conditions, i.e., glycine-NaOH buffer reduces color development in solutions of compound 1.


IN THE CLAIMS:

1. An aqueous pharmaceutical formulation suitable for intravenous injection comprising:
an anti-ulcerative compound having the following formula:



wherein R¹ and R² are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxy carbonyl, a carboxyl group, and halogen;


X is a member selected from the group consisting of -O-, -S- or



where R³ is a member selected from the group consisting of hydrogen, lower alkyl, phenyl, benzyl, and lower alkoxy carbonyl; and


Z is selected from the group consisting of:

(1) a group of the formula:




where p is an integer of 1 to 3 and R⁴ is a hydrogen atom or a lower alkyl, aryl or aralkyl group;

(2) a group of the general formula:




2 where q is an integer of 1 to 3 and R^5 is a halogen atom or an alkoxy carbonyl, aryl or
3 heteroaryl group;

4 (3) a group of the general formula:




6 where r and s each independently are an integer of 1 to 5 and R^6 is a hydrogen atom or a
7 lower alkyl group;

8
9
10
11 (4) a group of the formula:





12
13
14
15 (5) a group of the formula:




16

17


18




where t is an integer of 0 to 2 and A is a lower alkyl, alkoxycarbonylmethyl, pyridyl or furyl



where P is selected from the group consisting of: -NH-, -O- or -S-. or a group of the general formula:



wherein R⁷ is hydrogen or lower alkyl and w is from 0 to 3;

(8) a group of the general formula:  where R⁸ is an

acetoxyl or lower alkyl group; and

(9) a group of the general formula: -OR⁹


where R⁹ is a hydrogen atom or a lower alkyl or aryl group;

n is an integer of 0 to 2; m is an integer of 2 to 10, and

J and K are independently hydrogen or lower alkyl, with the proviso that when Z is a group falling under the above category (9), R⁹ is a lower alkyl group and m stands for an integer of 3 to 10, and pharmaceutically acceptable salts thereof; and glycine, in a pharmaceutically acceptable carrier.

2. An aqueous pharmaceutical formulation of claim 1 suitable for intravenous injection comprising:

an anti-ulcerative compound having the following formula:



- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10

4
5

6

7

8

9

10

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

3



8
9
10
11
12
13

wherein R^4 is selected from the group consisting of hydrogen, lower alkyl, aryl, and aralkyl;

wherein J is selected from the group consisting of hydrogen or lower alkyl;

wherein m is an integer from 2 to 10;

wherein p is an integer from 1 to 3;

and pharmaceutically acceptable salts thereof;

glycine, sodium hydroxide; and


a tonicity agent.

4. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 1 wherein said tonicity agent is selected from the group consisting of sodium chloride, glycerin, mannitol, sucrose, lactose, and dextrose.

5. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 2 wherein said tonicity agent is selected from the group consisting of sodium chloride and dextrose.

6. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 3 wherein said tonicity agent is selected from the group consisting of sodium chloride and dextrose.

7. The aqueous pharmaceutical formulation suitable for intravenous injection of claim 1 wherein said compound is



1 8. The aqueous pharmaceutical formulation suitable for intravenous
2 injection of claim 7 wherein said tonicity agent is selected from the group consisting of
3 sodium chloride and dextrose.

1 9. The aqueous pharmaceutical formulation suitable for intravenous
2 injection of claim 8 wherein said tonicity agent is sodium chloride and said sodium chloride
3 is present in said formulation at a concentration of about 0.9% by weight.


1 10. The aqueous pharmaceutical formulation suitable for intravenous
2 injection of claim 8 wherein said tonicity agent is dextrose and said dextrose is present in said
3 formulation at a concentration of about 5% by weight.

1 11. The aqueous pharmaceutical formulation suitable for intravenous
2 injection of claim 1 wherein said formulation has an alkaline pH, and wherein said glycine in
3 said formulation is present at a concentration of between about 1 mM and 300 mM.

1 12. The aqueous pharmaceutical formulation suitable for intravenous
2 injection of claim 4 wherein said formulation has a pH of between about 9 and about 12, and
3 wherein said glycine in said formulation is present at a concentration of between about 10
4 mM and 300 mM.

1 13. The aqueous pharmaceutical formulation suitable for intravenous
2 injection of claim 8 wherein said formulation has a pH of between about 9 and 12, and
3 wherein said glycine in said formulation is present at a concentration of between about 10
4 mM and 300 mM.

1 14. A method for stabilizing anti-ulcerative formulations suitable for
2 intravenous injection which comprises:
3 providing a compound of the formula
4




wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl, a carboxyl group, and halogen;

X is a member selected from the group consisting of $-O-$, $-S-$ or $\begin{array}{c} \text{---N---} \\ | \\ R^3 \end{array}$,

where R^3 is a member selected from the group consisting of hydrogen, lower alkyl, phenyl, benzyl, and lower alkoxycarbonyl; and


Z is selected from the group consisting of:

(1) a group of the formula:




where p is an integer of 1 to 3 and R^4 is a hydrogen atom or a lower alkyl, aryl or aralkyl group;

(2) a group of the general formula:



where q is an integer of 1 to 3 and R^5 is a halogen atom or an alkoxycarbonyl, aryl or heteroaryl group;

(3) a group of the general formula:



where r and s each independently are an integer of 1 to 5 and R^6 is a hydrogen atom or a

1 lower alkyl group;


2

3

4

5

(4) a group of the formula:




6

7

8

9

(5) a group of the formula:




10

11

12

13

(6) a group of the formula:




14

15


16

(7) a group of the general formula: $\begin{array}{c} \text{(O)}_t \\ \parallel \\ \text{---S---A} \end{array}$;


where t is an integer of 0 to 2 and A is a lower alkyl, alkoxycarbonylmethyl, pyridyl or furyl

group, or a group of the general formula:  ,

where P is selected from the group consisting of: -NH-, -O- or -S- or a group of the general formula:



wherein R⁷ is hydrogen or lower alkyl and w is from 0 to 3;

(8) a group of the general formula:  where R⁸ is

an


acetoxy or lower alkyl group; and

(9) a group of the general formula: $-OR^9$
 where R^9 is a hydrogen atom or a lower alkyl or aryl group;
 n is an integer of 0 to 2; m is an integer of 2 to 10, and
 J and K are independently hydrogen or lower alkyl, with the proviso that when
 Z is a group falling under the above category (9), R^9 is a lower alkyl group and m stands for
 an integer of 3 to 10, and pharmaceutically acceptable salts thereof;
 providing a solution suitable for intravenous injection which has a pH of
 between about 10 and 11 and which comprises glycine; and
 admixing said compound and said solution until said compound is dissolved in
 said solution.

15. The method of claim 14 wherein said solution contains a solute
 selected from the group consisting of dextrose and sodium chloride.

16. The method of claim 14 wherein said glycine is present in said solution
 at a concentration of between about 10 and about 300 mM.

17. The method of claim 14 wherein said compound is



18. The method of claim 17 wherein said solution contains a solute

1 selected from the group consisting of dextrose and sodium chloride.

1 19. The method of claim 18 wherein said glycine is present in said solution
2 at a concentration of between about 10 and about 300 mM.

1 20. The method of claim 19 wherein said solution contains a solute
2 selected from the group consisting of dextrose and sodium chloride, and wherein said
3 solution is isotonic with blood plasma.

1 21. The formulation of claim 1, which comprises a tonicity agent.

22. The formulation of claim 1, which comprises sodium hydroxide.

23. The method of claim 11, wherein said alkaline pH is between about 9
and about 12.

0044955-04400

ABSTRACT

The present invention provides pharmaceutical formulations suitable for intravenous injection comprising a lyophilized anti-ulcerative agent reconstituted in isotonic solutions suitable for intravenous administration, such as 5% dextrose or 0.9% sodium chloride. The solutions are brought to a pH of between about 9 and about 12, preferably between about pH 10 and 11, by a glycine-sodium hydroxide buffer. Such formulations are chemically and physically stable, and do not significantly change color, for at least between about 6 and about 12 hours at room temperature, and are stable to color change for from between about 24 and 48 hours if kept at 5 °C.

004740" 85864560

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8





FIG. 9



**DECLARATION
AND POWER OF ATTORNEY
Original Application**

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor if only one name is listed at 1 below, or a joint inventor if plural inventors are named below, of the invention entitled:

PHARMACEUTICAL FORMULATION COMPRISING GLYCINE AS A STABILIZER

which is described and claimed in:

<input checked="" type="checkbox"/> [X]	the attached specification, which is a continuation of International Application Serial No. PCT/US98/21972 filed September 14, 1998	<input type="checkbox"/> []	the specification in application Serial No. <small>(for declaration not accompanying application)</small>
---	---	-----------------------------	--

that I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application, that I acknowledge my duty to disclose information of which I am aware which is material to patentability in accordance with 37 CFR §1.56. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim the priority benefits under 35 U.S.C. §119 of any application(s) for patent or inventor's certificate listed below. All foreign applications for patent or inventor's certificate on this invention filed by me or my legal representatives or assigns prior to the application(s) of which priority is claimed are also identified below.

PRIOR APPLICATION(S), IF ANY, OF WHICH PRIORITY IS CLAIMED

<u>COUNTRY</u>	<u>APPLICATION NO.</u>	<u>DATE OF FILING</u>
U.S.	60/062,089	October 14, 1997

[illegible]COUNTRY

APPLICATION NO.

DATE OF FILING

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agents(s) to prosecute this application and transact all business in the Patent and Trademark office connected therewith: Gordon D. Coplein #19,165, William F. Dudme, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Marc S. Gross #19,614, Harold E. Wurst #22,183, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen #19,407, Henry Sternberg #22,408, Robert A. Green #28,301, Peter C. Schechter #31,662, Robert Schaffer #31,194, Robert C. Sullivan, Jr. #30,499, Ira J. Levy #35,587, Joseph R. Robinson #33,448, John C. Todaro #36,036, Scott J. Lindvall #40,325

all of the firm of DARBY & DARBY P.C., 805 Third Avenue, New York, NY 10022

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

John C. Todaro
212-527-7700

FULL NAME AND RESIDENCE OF INVENTOR 1

LAST NAME: McSHANE FIRST NAME: James MIDDLE NAME:

CITY: Wake Forest STATE OR FOREIGN COUNTRY: North Carolina COUNTRY OF CITIZENSHIP: U.S.

POST OFFICE ADDRESS: 8536 Wolverton Field Drive CITY: Wake Forest STATE OR COUNTRY: North Carolina ZIP CODE: 27587

FULL NAME AND RESIDENCE OF INVENTOR 2

LAST NAME: WOOD FIRST NAME: Ray MIDDLE NAME:

CITY: Raleigh STATE OR FOREIGN COUNTRY: North Carolina COUNTRY OF CITIZENSHIP: Canada

POST OFFICE ADDRESS: 3504 Timberwood Court CITY: Raleigh STATE OR COUNTRY: North Carolina ZIP CODE: 27606

FULL NAME AND RESIDENCE OF INVENTOR 3

LAST NAME: WATANABE FIRST NAME: Sumio MIDDLE NAME:
CITY: Fuso-cho, Aichi STATE OR FOREIGN COUNTRY: Japan COUNTRY OF CITIZENSHIP: Japan
POST OFFICE ADDRESS: 14-2 Nakayoshiike, Saito CITY: Fuso-cho, Aichi STATE OR COUNTRY: Japan ZIP CODE: 480-0104

FULL NAME AND RESIDENCE OF INVENTOR 4

LAST NAME: IWAMOTO FIRST NAME: Kiyoshi MIDDLE NAME:
CITY: Kagamihara-shi, Gifu STATE OR FOREIGN COUNTRY: Japan COUNTRY OF CITIZENSHIP: Japan
POST OFFICE ADDRESS: 8-121, Tsutsujigaoka CITY: Kagamihara-shi, Gifu STATE OR COUNTRY: Japan
ZIP CODE: 509-0131

FULL NAME AND RESIDENCE OF INVENTOR 5

LAST NAME: ONAI FIRST NAME: Katsumi MIDDLE NAME:
CITY: Aichi STATE OR FOREIGN COUNTRY: Japan COUNTRY OF CITIZENSHIP: Japan
POST OFFICE ADDRESS: 211-1, Tougou, Kadama CITY: Aichi STATE OR COUNTRY: Japan
ZIP CODE: 493-0002

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 1: _____ DATED: _____
James McSHANE

SIGNATURE OF INVENTOR 2: _____ DATED: _____
Ray WOOD

SIGNATURE OF INVENTOR 4: _____ DATED: _____
Kiyoshi IWAMOTO

Sociodemographic characteristics		Health status		Healthcare utilization		Healthcare expenditure		Healthcare expenditure per capita			
Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)	Variable	Mean (SD)		
Age	65.2 (10.5)	Gender	Male	55.1 (10.2)	Female	54.8 (10.3)	Health insurance	Yes	55.5 (10.1)	No	54.9 (10.4)
Marital status	Married	55.3 (10.1)	Unmarried	54.7 (10.3)	Health insurance	Yes	55.5 (10.1)	No	54.9 (10.4)		
Education	High school	55.4 (10.2)	College	54.8 (10.3)	Health insurance	Yes	55.5 (10.1)	No	54.9 (10.4)		
Income	Low	55.6 (10.3)	High	54.9 (10.2)	Health insurance	Yes	55.5 (10.1)	No	54.9 (10.4)		
Health status	Good	55.7 (10.4)	Fair	54.8 (10.3)	Health insurance	Yes	55.5 (10.1)	No	54.9 (10.4)		
Healthcare utilization	High	55.8 (10.5)	Low	54.9 (10.2)	Health insurance	Yes	55.5 (10.1)	No	54.9 (10.4)		
Healthcare expenditure	High	55.9 (10.6)	Low	54.8 (10.3)	Health insurance	Yes	55.5 (10.1)	No	54.9 (10.4)		
Healthcare expenditure per capita	High	56.0 (10.7)	Low	54.7 (10.2)	Health insurance	Yes	55.5 (10.1)	No	54.9 (10.4)		